Navigation Links
Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension

* New data from 741-patient trial show those treated with Prexige experienced significantly smaller impact on blood pressure compared to ibuprofen[1]

* Many patients with osteoarthritis also have high blood pressure; even small changes in blood pressure can impact cardiovascular risk[2],[3]

* Prexige approved in more than 50 countries and currently under review in US for use in osteoarthritis patients

BASEL, Switzerland, June 15, 2007 - Patients with osteoarthritis who also have controlled hypertension experienced a slight decrease in average daily blood pressure when treated with the selective COX-2 inhibitor Prexige® (lumiracoxib) compared to a slight increase in those taking ibuprofen, a commonly-used non-steroidal anti-inflammatory drug (NSAID)[1].

These new results, presented today at the Annual European Congress of Rheumatology (EULAR) in Barcelona, are important because around 40% of patients with osteoarthritis also have high blood pressure (or hypertension)[4],[5].

Independent research shows that even small elevations in blood pressure can contribute to an increased risk of cardiovascular events[2],[3],[6],[7],[8]. Osteoarthritis is the most common form of arthritis affecting 139 million people worldwide[9].

"NSAIDs, including some COX-2s, have been associated with raised blood pressure, and this effect may be in part responsible for the increased risk of cardiovascular disease associated with this class of medications," said Tom MacDonald, Ph.D., Professor of Clinical Pharmacology at the Hypertension Research Centre at Ninewells Hospital & Medical School in Dundee, Scotland. "These data indicate that lumiracoxib may have less impact on blood pressure than the most commonly used NSAID ibuprofen."

Prexige, which is given to patients as a 100 mg once-daily tablet, is approved for use in certain types of patients with osteoarthritic pain of the knee
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/10/2014)... NEWPORT NEWS, Virginia , 11. ... führender Hersteller von Kameras für die ... Brust (MBI/BSGI), hat heute die CE-Zulassung ... Mit dem CE-Zeichen kann Dilon das ... seinen Vertriebsbereich auf den Großteil der ...
(Date:7/10/2014)... Yesterday, former Congressman Patrick Kennedy ... facility. Rep. Kennedy and Dick Moberg ... research in neurological disease and treatment. ... Garen Staglin , created One Mind, a ... that will radically accelerate the development and implementation ...
(Date:7/10/2014)... 2014   LabStyle Innovations Corp . (OTCQB:DRIO), developer ... the appointment of Professor Richard B. Stone ... of Directors. Prof. Stone brings over ... LabStyle as an entrepreneur, venture capitalist public, company ... expert. He currently serves on the board of ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4
... half of,health care workers get an annual flu shot, ... and the federal Centers for Disease,Control of the need ... is plenty of vaccine available this season, so there ... shot," said Joanne Grossi, deputy,secretary for health promotion and ...
... COGENT Trials To Enroll 4,000 Patients Worldwide, ... announced today it is launching a global Phase ... of its novel combination therapy CGT-2168.,The program, which ... 4,000 patients at hundreds of sites in the ...
Cached Medicine Technology:State, Federal Officials Remind Health Care Workers, Other at-Risk Individuals to Get Annual Flu Shot 2Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 For those who ... bodies can readily absorb the nutrients in food. The enzymes ... that are small enough to be absorbed by human bodies. ... a lack of enzymes in regular food is the cause ... product that was started by Michelle DelPresto, a mother of ...
(Date:7/12/2014)... Salt Lake City, Utah (PRWEB) July 12, 2014 ... Five spotlighted two types of startups, with awards being ... UVEF’s new emphasis spotlighted Utah’s outstanding entrepreneur community with ... are proving a sustainable model with incoming revenue. , ... companies from across the state that are under 5 ...
(Date:7/12/2014)... 2014 Restore My Vision Today is ... Pearson, a couple boasting very impressive credentials on the ... Vision Today as a way to help consumers do ... in their respective patients’ treatments . , ... “secret” trove of pertinent information relevant to eye care ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
(Date:7/11/2014)... July 11, 2014 As transvaginal ... against Johnson & Johnson’s Ethicon Inc. unit continue ... notes that the Texas Attorney General’s Office has ... of surgical mesh products used to treat pelvic ... a report from kens5.com, the probe began nearly ...
Breaking Medicine News(10 mins):Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4
... Onchocerciasis, river blindness or craw craw is endemic to ... weakening// in affected individuals thus rendering them listless and ... the economy of this area. The disease is caused ... the bite of the black fly, Simulium. ...
... study published by scientists from California University in the ... re-evaluation//. Scientist have discovered that the virus evaded ... intestinal tissue of patients, where it continued to replicate ... showed that the antiretrovirals were working. ...
... iodine dose to cure deadly brain tumors such as ... is used as carriers for radioactive iodine. The first ... was conducted by under Adam N. Mamelak, M.D., a ... About 18 patients participated in the trial and it ...
... patient was discharged for a week after undergoing successful surgery, ... Guoxing, 30, who had not seen his wife and two ... returned home Friday for a week-long visit to his family ... his face is alive and Li has been doing well, ...
... – The accomplishments of Thailand and Cambodia in the ... achieved primarily through the extensive use of condoms.// ... Singapore's Ministry of Health, said "The 100 per cent ... prominent examples of successful prevention efforts." ,In ...
... been the cornerstones of managing type 2 diabetes. But ... ,Now, a new systematic review shows that exercise ... sensitivity to insulin, and decreases blood lipids (fats) while ... 2 diabetes is an increasing problem in Western societies ...
Cached Medicine News:Health News:Onchocerciasis: Presentation And Treatment 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 2Health News:New Carrier Developed To Deliver Drugs to Gliomas 3Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3
Blood grouping tubes are available in two formulations, ACD-A, ACD-B or with a CPDA solution. Blood grouping tubes are for blood grouping determinations and also for cell preservation....
BD Vacutainer® Specialty Tubes - Other - Glass...
BD Vacutainer® Specialty Tubes - Other - Plastic...
BD Vacutainer® Specialty Tubes - Lead Testing...
Medicine Products: